{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:33:13Z","timestamp":1765546393063,"version":"build-2065373602"},"reference-count":85,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Mallinckrodt"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.det.2018.07.006","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T17:41:25Z","timestamp":1541094085000},"page":"37-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Connective Tissue Disease"],"prefix":"10.1016","volume":"37","author":[{"given":"Anthony P.","family":"Fernandez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2018.07.006_bib1","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.det.2018.07.006_bib2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2018.07.006_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2018.07.006_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2017.12.055","article-title":"Applicability of EULAR\/ACR classification criteria for dermatomyositis to amyopathic disease","volume":"79","author":"Patel","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11926-014-0465-0","article-title":"Amyopathic dermatomyositis: definitions diagnosis and management","volume":"16","author":"Bailey","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.det.2018.07.006_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/bjd.13167","article-title":"Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life","volume":"172","author":"Robinson","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3899\/jrheum.160688","article-title":"Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with\u00a0persistent skin rash","volume":"44","author":"Huber","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.det.2018.07.006_bib8","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/rheumatology\/keu146","article-title":"Disease activity and prognostic factors in juvenile dermatomyositis: a longterm follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool","volume":"53","author":"Sanner","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.det.2018.07.006_bib9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/art.23829","article-title":"The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis","volume":"59","author":"Seshadri","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.det.2018.07.006_bib10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2017.3758","article-title":"Factors associated with clinical remission of skin disease in dermatomyositis","volume":"154","author":"Wolstencroft","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib11","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1056\/NEJMc1412997","article-title":"Remission of recalcitrant dermatomyositis treated with ruxolitinib","volume":"371","author":"Hornung","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2018.07.006_bib12","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/annrheumdis-2017-212047","article-title":"Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis","volume":"77","author":"Aggarwal","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.det.2018.07.006_bib14","unstructured":"Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis (Acthar Gel). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02245841. Accessed June 27, 2018."},{"key":"10.1016\/j.det.2018.07.006_bib15","article-title":"Potent anti-inflammatory and pro-resolving effects of anabasum in a human model of self-resolving acute inflammation","author":"Motwani","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"suppl 10","key":"10.1016\/j.det.2018.07.006_bib16","article-title":"A\u00a0phase 2 study of safety and efficacy of anabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis","volume":"69","author":"Werth","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.det.2018.07.006_bib17","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/annrheumdis-2018-eular.5629","article-title":"SAT0512 Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated in an open label extension of trial JBT101-DM-001","volume":"77","author":"Werth","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.det.2018.07.006_bib18","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon B in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib19","doi-asserted-by":"crossref","first-page":"e29161","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.det.2018.07.006_bib20","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/ard.2010.139949","article-title":"Interferon beta is associated with type 1 interferon-inducible gene expression in dermatomyositis","volume":"70","author":"Liao","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.det.2018.07.006_bib21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A\u00a0phase 1b clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients","volume":"73","author":"Higgs","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.det.2018.07.006_bib22","unstructured":"Adis Insight. Sifalimumab. Available at: https:\/\/adisinsight.springer.com\/drugs\/800024071."},{"issue":"5, Suppl","key":"10.1016\/j.det.2018.07.006_bib23","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.jid.2018.03.443","article-title":"Scalp neuropathy in dermatomyositis patients with recalcitrant scalp pruritus","volume":"138","author":"Cirino","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.16498","article-title":"Itch in dermatomyositis: the role of increased skin interleukin-31","author":"Kim","year":"2018","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2018.07.006_bib25","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1177\/0961203310370048","article-title":"Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates","volume":"19","author":"Obermoser","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.det.2018.07.006_bib26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jaad.2017.02.030","article-title":"Development of classification criteria for discoid lupus erythematosus: results of a delphi exercise","volume":"77","author":"Elman","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib27","doi-asserted-by":"crossref","first-page":"2392e402","DOI":"10.1038\/jid.2008.96","article-title":"An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in \u201cinterface dermatitis\u201d","volume":"128","author":"Wenzel","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00281-015-0550-0","article-title":"Lupus erythematosus revisited","volume":"38","author":"Kuhn","year":"2016","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.det.2018.07.006_bib29","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.jid.2017.03.018","article-title":"Immunostimulatory endogenous nucleic acids drive the lesional inflammation in cutaneous lupus erythematosus","volume":"137","author":"Scholtissek","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fimmu.2016.00035","article-title":"Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE","volume":"7","author":"Mahajan","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.det.2018.07.006_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jid.2016.09.008","article-title":"Lupus skin is primed for IL-6 inflammatory responses through a keratinocytes-mediated autocrine type I interferon loop","volume":"137","author":"Stannard","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/0049-0172(89)90050-4","article-title":"The use of quinacrine (Atrabine) in rheumatic diseases: a reexamination","volume":"18","author":"Wallace","year":"1989","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.det.2018.07.006_bib33","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.jisp.2016.11.001","article-title":"Quinacrine suppresses tumor necrosis factor-\u03b1 and IFN-\u03b1 in dermatomyositis and cutaneous lupus erythematosus","volume":"18","author":"Alves","year":"2017","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"key":"10.1016\/j.det.2018.07.006_bib34","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.det.2018.07.006_bib35","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.det.2018.07.006_bib36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/art.40018","article-title":"Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial","volume":"69","author":"Yokogawa","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.det.2018.07.006_bib37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaad.2017.08.045","article-title":"Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: a multicenter observational study","volume":"78","author":"Chasset","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib38","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/archdermatol.2011.191","article-title":"Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis","volume":"147","author":"Chang","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib39","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjd.15312","article-title":"Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis","volume":"177","author":"Chasset","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/archdermatol.2011.2558","article-title":"Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study","volume":"148","author":"Frances","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib41","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jaad.2015.09.064","article-title":"The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): an open-label prospective pilot study","volume":"74","author":"Chasset","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib42","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamadermatol.2017.1160","article-title":"Characteristics and alternative treatment outcomes of antimalarial-refractory cutaneous lupus erythematosus","volume":"153","author":"Fruchter","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib43","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1111\/ijd.13226","article-title":"Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience","volume":"55","author":"Kindle","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib44","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jaad.2016.01.054","article-title":"Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients","volume":"74","author":"Fennira","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib45","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jaad.2017.09.059","article-title":"Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: a systematic review and meta-analysis","volume":"78","author":"Chasset","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib46","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.4049\/jimmunol.1601725","article-title":"Aiolos overexpression in systemic lupus erythematosus B cell subtypes and BAFF-induced memory B cell differentiation are reduced by CC-220 modulation of cereblon activity","volume":"199","author":"Nakayama","year":"2017","journal-title":"J\u00a0Immunol"},{"issue":"suppl 10","key":"10.1016\/j.det.2018.07.006_bib47","article-title":"CC-220 decreases B-cell subsets and plasmacytoid dendritic cells in systemic lupus erythematosus (SLE) patients and is associated with skin improvement: pharmacodynamic results from a phase IIa proof of concept study.","volume":"69","author":"Werth","year":"2017","journal-title":"(abstract) Arthritis Rheumatol"},{"key":"10.1016\/j.det.2018.07.006_bib48","unstructured":"A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03161483."},{"key":"10.1016\/j.det.2018.07.006_bib49","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.37824","article-title":"Sifalimumab, a human anti-interferon-\u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.det.2018.07.006_bib50","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.det.2018.07.006_bib51","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"CD1013 study investigators. anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.det.2018.07.006_bib52","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4065\/70.11.1068","article-title":"Classification of morphea (localized scleroderma)","volume":"70","author":"Peterson","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.det.2018.07.006_bib53","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/01.bor.0000245727.40630.c3","article-title":"Localized scleroderma","volume":"18","author":"Laxer","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.det.2018.07.006_bib54","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jaad.2016.08.052","article-title":"Skin mapping for the classification of generalized morphea","volume":"78","author":"Teske","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5 Suppl","key":"10.1016\/j.det.2018.07.006_bib55","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jid.2018.03.031","article-title":"Myelin basic protein antibodies as a biomarker in Morphea","volume":"138","author":"Burger","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib56","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jaad.2016.12.020","article-title":"Histopathological changes in morphea and their clinical correlates: results from the Morphea in adults and children cohort V","volume":"76","author":"Walker","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib57","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.jid.2017.04.008","article-title":"Transcriptional and cytokine profiles identify CXCL9 as a biomarker of disease activity in Morphea","volume":"137","author":"O\u2019Brien","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib58","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jaad.2015.12.051","article-title":"Characterization of patients with clinical overlap of morphea and systemic sclerosis: a case series","volume":"74","author":"Chen","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5 Suppl","key":"10.1016\/j.det.2018.07.006_bib59","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.jid.2018.03.343","article-title":"Body site distribution of pediatric-onset morphea","volume":"138","author":"Kiguradze","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.07.006_bib60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaad.2018.03.005","article-title":"Inflammatory arthritis in pediatric patients with morphea","volume":"79","author":"Kashem","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.det.2018.07.006_bib61","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/art.21264","article-title":"Localized scleroderma in childhood is not just a skin disease","volume":"52","author":"Zulian","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.det.2018.07.006_bib62","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/bjd.13572","article-title":"Health-related quality of life in morphoea","volume":"172","author":"Klimas","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib63","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/pde.13281","article-title":"Discordance of pediatric morphea treatment by pediatric dermatologists","volume":"35","author":"Tollefson","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib64","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jaad.2014.11.019","article-title":"Attitudes and trends in the treatment of morphea: a national survey","volume":"72","author":"Strickland","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib65","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1002\/art.38853","article-title":"Comparison of outcomes in adults with pediatric-onset morphea and those with adult-onset Morphea","volume":"66","author":"Condie","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.det.2018.07.006_bib66","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.semarthrit.2016.08.018","article-title":"Early- and late-stage morphea subtypes with deep tissue involvement is treatable with Abatacept (Orencia)","volume":"46","author":"Adeeb","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.det.2018.07.006_bib67","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2340\/00015555-1136","article-title":"Abatacept is a promising treatment for patients with disseminated morphea profunda: presentation of two cases","volume":"91","author":"Stausb\u00f8l-Gr\u00f8n B","year":"2011","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.det.2018.07.006_bib68","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.det.2018.07.006_bib69","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/rheumatology\/kex382","article-title":"Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma","volume":"57","author":"Lythgoe","year":"2018","journal-title":"Rheumatology"},{"issue":"Suppl. 106","key":"10.1016\/j.det.2018.07.006_bib70","first-page":"S211","article-title":"Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases?","volume":"35","author":"Martini","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.det.2018.07.006_bib71","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2005.11.1063","article-title":"A\u00a0randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma","volume":"54","author":"Kreuter","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib72","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2133.2009.09438.x","article-title":"Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study","volume":"162","author":"Andres","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib73","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jaad.2013.10.018","article-title":"Recurrence of morphea after successful ultraviolet A1 phototherapy: a cohort study","volume":"70","author":"Vasquez","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.07.006_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.det.2018.07.006_bib75","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/art.40375","article-title":"Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 Revised international chapel hill consensus conference nomenclature of vasculitides","volume":"70","author":"Sunderk\u00f6tter","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.det.2018.07.006_bib76","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/art.1780330809","article-title":"The American College of Rheumatology 1990 criteria for the classification of vasculitis","volume":"33","author":"Mills","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.det.2018.07.006_bib77","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/ard.2009.116657","article-title":"EULAR\/PRINTO\/PRES criteria for Henoch\u2013Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria","volume":"69","author":"Ozen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.det.2018.07.006_bib78","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/cup.13054","article-title":"Direct immunofluorescence testing in vasculitis\u2014A single institution experience with Henoch-Sch\u00f6nlein purpura","volume":"45","author":"Feasel","year":"2018","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.det.2018.07.006_bib79","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jaad.2011.11.946","article-title":"Correlates of systemic disease in adult Henoch-Sch\u00f6nlein purpura: a retrospective study of direct immunofluorescence and skin lesion distribution in 87 patients at Mayo Clinic","volume":"67","author":"Poterucha","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib80","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jaad.2009.11.690","article-title":"IgM in lesional skin of adults with Henoch-Sch\u00f6nlein purpura is an indication of renal involvement","volume":"63","author":"Takeuchi","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib81","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1684\/ejd.2013.2243","article-title":"The correlation between cutaneous IgM deposition and renal involvement in adult patients with Henoch-Sch\u00f6nlein purpura","volume":"24","author":"Belli","year":"2014","journal-title":"Eur J Dermatol"},{"issue":"11","key":"10.1016\/j.det.2018.07.006_bib82","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamadermatol.2017.2105","article-title":"Prevalence and characteristics of nonblanching, palpable skin lesions with a linear pattern in children with Henoch-Sch\u00f6nlein syndrome","volume":"153","author":"Milani","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.det.2018.07.006_bib83","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archderm.1995.01690240061009","article-title":"Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial","volume":"131","author":"Sais","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2018.07.006_bib84","unstructured":"Clinical Transcriptomics in Systemic Vasculitis (CUTIS). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03004326."},{"key":"10.1016\/j.det.2018.07.006_bib85","unstructured":"A Randomized Multicenter Study for Isolated Skin Vasculitis (ARAMIS). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02939573."}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863518310970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863518310970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:44:22Z","timestamp":1760006662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863518310970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0733863518310970"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2018.07.006","relation":{},"ISSN":["0733-8635"],"issn-type":[{"type":"print","value":"0733-8635"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Connective Tissue Disease","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2018.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}